The multinational is teaming up with Aspect Biosystems to leverage the companies proprietary bioprinting system to develop tissue therapeutics specifically aimed at diabetes and obesity.

It’s not exactly clear yet what this work will entail, but it seems like a growing trend of using bioprinting in the space, and if the money involved is anything to go by this seems like a very large area of interest.

The deal between the two companies gives Aspect $75 million in initial payments, with extra future milestone payments and royalties totalling in at over $2.6 billion.

https://www.aspectbiosystems.com/news-resources/novo-nordisk-partnership-to-develop-bioprinted-tissue-therapeutics-for-diabetes-and-obesity
https://www.youtube.com/@AspectBiosystems/videos